TITRIMETRIC DETERMINATION OF HEPARIN IN WHOLE BLOOD

全血中肝素的滴定量测定

• 批准号: 2644913
• 负责人: GLENN B MARTIN
• 金额: $ 9.87万
• 依托单位: SELECTIVE TECHNOLOGIES, INC.
• 依托单位国家: 美国
• 财政年份: 1998
• 资助国家: 美国
• 起止时间: 1998-06-01 至 1999-04-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/2644913
• 关键词: analytical method; diagnosis design /evaluation; diagnostic tests; heparin; human tissue; hydropathy; ionophores; method development; polymers; protamines; serology /serodiagnosis

The objective of this project is to develop a simple, quantitative point-of-care test for heparin, a drug that is used to prevent clotting during most surgical procedures, especially those requiring an extracorporeal loop. As the continued presence of free heparin after surgery is dangerous to the patient, protamine is usually administered to reverse the anticoagulant effect of heparin at the conclusion of surgery. The method most often used for heparin measurement is a non- specific bioassay that measures activated clotting time of a patient's blood. Phase I studies will demonstrate the feasibility of measuring heparin in whole blood samples using protamine titration in a disposable cartridge. The titration end-point is determined by an optical reflectance measurement of a protamine-specific chromoionophore incorporated into a lipophilic polymer cast onto a highly reflective membrane. Heparin is titrated with several cartridges containing varying amounts of protamine which complexes the free heparin of the sample, and the presence of any excess protamine is then measured. In Phase II we will construct a prototype instrument that can automatically perform a protamine titration of heparin in whole blood samples. PROPOSED COMMERCIAL APPLICATION Practical point-of-care instrumentation that could directly monitor heparin levels in whole blood samples from patients would be extremely useful in the management of heparinized patients. Compared to the current bioassay, the proposed optical sensor offers much better specificity, thereby eliminating a large degree of uncertainty in assessing the cause of patient bleeding and consequently the over- prescription of protamine.

该项目的目标是开发一个简单的，定量的 肝素的即时检测，一种用于防止凝血的药物 在大多数外科手术中，尤其是那些需要 体外循环 由于游离肝素的持续存在， 手术对病人是危险的，鱼精蛋白通常是管理 在结束时逆转肝素的抗凝作用， 手术最常用于肝素测量的方法是非- 一种特定的生物测定法，用于测量患者的活化凝血时间， 血 第一阶段研究将证明测量的可行性 一次性使用鱼精蛋白滴定法测定全血样本中的肝素 弹药筒 滴定终点由光学测定仪测定。 鱼精蛋白特异性色素离子载体的反射率测量 将其纳入亲脂性聚合物中，浇铸在高反射率的 膜的肝素是用几个含有不同浓度的试剂盒滴定的。 与样品的游离肝素络合的鱼精蛋白的量，和 然后测量任何过量鱼精蛋白的存在。 在第二阶段，我们 将建造一个原型仪器，可以自动执行 全血样本中肝素的鱼精蛋白滴定。 建议的商业应用 可直接监测的实用床旁仪器 患者全血样本中的肝素水平 可用于肝素化患者的管理。相比 目前的生物测定，提出的光学传感器提供了更好的 特异性，从而消除了很大程度的不确定性， 评估患者出血的原因，并因此过度- 鱼精蛋白的处方